"Cancer Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
| Descriptor ID |
D019496
|
| MeSH Number(s) |
D20.215.894.200
|
| Concept/Terms |
Cancer Vaccines- Cancer Vaccines
- Vaccines, Tumor
- Vaccines, Neoplasm
- Tumor Vaccines
- Vaccines, Cancer
- Neoplasm Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Cancer Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Cancer Vaccines".
This graph shows the total number of publications written about "Cancer Vaccines" by people in this website by year, and whether "Cancer Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 4 | 2 | 6 |
| 1998 | 8 | 3 | 11 |
| 1999 | 4 | 1 | 5 |
| 2000 | 7 | 3 | 10 |
| 2001 | 12 | 4 | 16 |
| 2002 | 12 | 3 | 15 |
| 2003 | 14 | 9 | 23 |
| 2004 | 11 | 6 | 17 |
| 2005 | 11 | 8 | 19 |
| 2006 | 20 | 9 | 29 |
| 2007 | 18 | 5 | 23 |
| 2008 | 16 | 9 | 25 |
| 2009 | 22 | 9 | 31 |
| 2010 | 19 | 6 | 25 |
| 2011 | 30 | 5 | 35 |
| 2012 | 14 | 5 | 19 |
| 2013 | 10 | 2 | 12 |
| 2014 | 21 | 5 | 26 |
| 2015 | 6 | 3 | 9 |
| 2016 | 8 | 8 | 16 |
| 2017 | 12 | 6 | 18 |
| 2018 | 11 | 5 | 16 |
| 2019 | 15 | 4 | 19 |
| 2020 | 11 | 5 | 16 |
| 2021 | 15 | 0 | 15 |
| 2022 | 7 | 0 | 7 |
| 2023 | 7 | 0 | 7 |
| 2024 | 7 | 5 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cancer Vaccines" by people in Profiles.
-
Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity. Int Immunopharmacol. 2024 Dec 05; 142(Pt A):113004.
-
Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity. J Control Release. 2024 Oct; 374:550-562.
-
B cell-based therapy produces antibodies that inhibit glioblastoma growth. J Clin Invest. 2024 Aug 29; 134(20).
-
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors. J Immunother Cancer. 2024 Aug 28; 12(8).
-
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. Nat Commun. 2024 Aug 11; 15(1):6874.
-
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy. Future Oncol. 2024; 20(29):2149-2164.
-
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature. 2024 Aug; 632(8023):182-191.
-
A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma. Cancer. 2024 Nov 15; 130(22):3845-3854.
-
The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2024 Jul-Aug; 22(6):291-293.
-
Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Science. 2024 Jun 28; 384(6703):eadh4567.